PHP
SAGE

Parkman Healthcare Partners’s Sage Therapeutics SAGE Stock Holding History

Parkman Healthcare Partners’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-70,033
Closed -$3.29M – 110
2023
Q2 		$3.29M Buy
70,033
+44,712
+177% +$2.22M 0.57% 55
2023
Q1 		$1.06M Buy
+25,321
New +$1.09M 0.23% 71
2020
Q2 		– Sell
-75,000
Closed -$2.15M – 84
2020
Q1 		$2.15M Buy
+75,000
New +$4.34M 1% 34

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Parkman Healthcare Partners's SAGE Position: Q3 2023 in Review

Parkman Healthcare Partners sold out of Sage Therapeutics (SAGE) in Q3 2023, closing a stake of 70,033 shares — an estimated $3.29M sold.

Parkman Healthcare Partners first reported a position in SAGE in Q1 2020 and held it in 3 quarters. The position peaked at $3.29M in Q2 2023. 194 funds tracked by Wall St. Rank hold SAGE as of Q3 2023.

  • Parkman Healthcare Partners reported no remaining Sage Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Parkman Healthcare Partners sold 70,033 Sage Therapeutics shares in Q3 2023, an estimated $3.29M.
  • Parkman Healthcare Partners first reported a position in Sage Therapeutics in Q1 2020 and held it in 3 quarters.
  • Parkman Healthcare Partners's Sage Therapeutics position peaked at $3.29M in Q2 2023.
  • 194 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2023.

Based on Parkman Healthcare Partners's 13F filing for Q3 2023, filed 14 Nov 2023.